PharmaTher Develops 3D-Printed Oral Peptide Products
The new peptide portfolio uses 3D printing to ensure targeted colonic delivery of specific medicinal compounds.
Updated on Oct. 29, 2026 in Biotech
PharmaTher Holdings Ltd. announced it is developing a new line of 3D-printed oral peptide products, including KPV and BPC-157. The products utilize proprietary technology to bypass the stomach and release directly in the colon.
Why it matters
This development follows a new policy from the U.S. Department of Health and Human Services that allows qualified pharmacies to compound six specific peptides. PharmaTher is leveraging this regulatory pathway to enable near-term commercialization.
The oral products use the patent-pending CORR3CT technology within the M3DICINES 3D-printed platform to facilitate colonic targeting. This design ensures that peptides like KPV and BPC-157 remain stable through the gastric system.
The players
PharmaTher Holdings Ltd.
This is a biotech company focused on developing specialized peptide-based therapies.
Craft Health Pte. Ltd.
This organization developed the CORR3CT technology used to facilitate targeted delivery.
U.S. Department of Health and Human Services
This federal agency established the conditional pathway for compounding specific peptides.
The details
The development aims to capitalize on a specific regulatory framework that permits Section 503A pharmacies to compound restricted peptides for patient use. By utilizing 3D-printed delivery mechanisms, the company seeks to solve traditional challenges regarding the oral stability of peptide-based treatments.
Timeline
October 29, 2026: PharmaTher announced the peptide portfolio development.
The Tech Race
The integration of 3D-printing into pharmaceutical manufacturing represents a move away from traditional pill production toward highly specialized, personalized medicine. This positions PharmaTher to compete by leveraging new regulatory pathways for high-precision delivery systems.
Patients may gain access to easier-to-administer oral versions of KPV and BPC-157 through qualified compounding pharmacies. This shift could simplify treatment routines for those currently reliant on injectable formats of these peptides.
The takeaway
Advancements in 3D-printed drug delivery are streamlining the way specialized peptides are administered to patients. Readers interested in peptide therapy should consult with their healthcare providers regarding the availability of compounded options under current federal guidelines.
Further reading
Learn more about advancements in Biotech to see how 3D printing is changing pharmaceutical production.
Source note: This article includes information reported by The Kingston Whig-Standard.
